Atsena Presents Positive 18-Month Results from Part A of the Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis
18-month results from Part A of LIGHTHOUSE Trial reinforce ATSN-201’s favorable safety profile and durable structural and functional benefits in patients with X-linked retinoschisis
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- FBG Bid Co. LLC Announces the Launch of OHG Brands
- TABOOLA.COM LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Urges Taboola.com Ltd. Investors with Large Losses to Contact the Firm
- Bragar Eagel & Squire, P.C. Encourages GoDaddy Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 20th
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,400+ feeds — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →